Basic Stats
| LEI | 549300TZTYD2PYN92D43 |
| CIK | 1145197 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Insulet Corporation
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Reg |
|
| August 7, 2025 |
Exhibit 99.1 Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1) Raising Full Year Revenue and Adjusted Operating Margin Guidance ACTON, Mass. - August 7, 2025 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 7, 2025 |
Offer Letter between Lisa Blair Davis and Insulet Corporation, dated June 27, 2025 Exhibit 10.7 June 27, 2025 Lisa Blair Davis [address on file] Dear Lisa, Insulet Corporation is pleased to offer you the full-time position of SVP, Chief Human Resources Officer, reporting directly to Ashley McEvoy, President and CEO, effective July 8, 2025. We are excited about the prospect of you joining Insulet and look forward to your meaningful contribution to the team. Your principal place o |
|
| June 9, 2025 |
Exhibit 10.1 Execution Version EIGHTH AMENDMENT TO CREDIT AGREEMENT EIGHTH AMENDMENT (this “Agreement”), dated as of June 6, 2025, among INSULET CORPORATION, a Delaware corporation (the “Borrower”), each Guarantor party hereto, the Lenders party hereto, each L/C Issuer and Swingline Lender party hereto and Morgan Stanley Senior Funding, Inc., as administrative agent for the Lenders (in such capaci |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2025 INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33462 04-3523891 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 9, 2025 |
Exhibit 10.2 CALL OPTION TERMINATION AGREEMENT dated as of [], 2025 Between INSULET CORPORATION and [] THIS CALL OPTION TERMINATION AGREEMENT (this “Agreement”) with respect to the Base Call Option Confirmation (as defined below) is made as of [], 2025, between Insulet Corporation (“Company”) and [] (“Dealer”). WHEREAS, Company issued $800,000,000 principal amount of 0.375% Convertible Senior Note |
|
| May 29, 2025 |
Insulet Corporation Conflict Minerals Report For Calendar Year 2024 Exhibit 1.01 Insulet Corporation Conflict Minerals Report For Calendar Year 2024 Insulet Corporation (“Insulet,” the “Company,” “we,” “us,” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2024 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (the “SEC”) |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-33462 04-3523891 (Commission File Number) (I.R.S. Employer Identification No.) 100 Nagog Park Acton, Massachusetts 01720 (Address of princi |
|
| May 28, 2025 |
Form of Insulet Corporation 2025 Stock Option and Incentive Plan Restricted Stock Unit Agreement EXHIBIT 10.2 INSULET CORPORATION 2025 STOCK OPTION AND INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT COVER SHEET Insulet Corporation, a Delaware corporation (the “Company”), hereby grants restricted stock units (“RSUs”) for shares of the Company’s common stock, par value $0.001 (the “Stock”), to you, subject to the vesting and other conditions set forth below and in the attached Restricted Stock |
|
| May 28, 2025 |
EXHIBIT 10.1 INSULET CORPORATION 2025 STOCK OPTION AND INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT Cover Sheet Insulet Corporation, a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Stock”), to you, subject to the vesting and other conditions set forth in this Insulet Corporation |
|
| May 28, 2025 |
Form of Insulet Corporation 2025 Stock Option and Incentive Plan Performance Stock Unit Agreement EXHIBIT 10.3 INSULET CORPORATION 2025 STOCK OPTION AND INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT Name of Grantee: «FirstName» «LastName» Number of Restricted Stock Units Granted: «UnitsGranted»(the “Target Award”) Grant Date: «GrantDate» Pursuant to the Insulet Corporation 2025 Stock Option and Incentive Plan (the “Plan”), Insulet Corporation (the “Company”) hereby grants an award under Sect |
|
| May 28, 2025 |
EXHIBIT 10.4 INSULET CORPORATION 2025 STOCK OPTION AND INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT COVER SHEET Insulet Corporation, a Delaware corporation (the “Company”), hereby grants restricted stock units (“RSUs”) for shares of the Company’s common stock, par value $0.001 (the “Stock”), to you, subject to the vesting and other conditions set forth below and in the attached Restricted Stock |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33462 04-3523891 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 22, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) INSULET CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 Par |
|
| May 22, 2025 |
Insulet Corporation 2025 Stock Option and Incentive Plan Exhibit 99.1 INSULET CORPORATION 2025 STOCK OPTION AND INCENTIVE PLAN 1 INSULET CORPORATION 2025 STOCK OPTION AND INCENTIVE PLAN 1.PURPOSE The Plan is intended to (a) provide eligible individuals with an incentive to contribute to the success of the Company and its Subsidiaries and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and pro |
|
| May 22, 2025 |
As filed with the Securities and Exchange Commission on May 22, 2025 As filed with the Securities and Exchange Commission on May 22, 2025 Registration No. |
|
| May 9, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Re |
|
| May 8, 2025 |
Year-Over-Year (30% Constant Currency1) Raising Full Year Revenue and Gross Margin Guidance Exhibit 99.1 Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1) Raising Full Year Revenue and Gross Margin Guidance ACTON, Mass. - May 8, 2025 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 29, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate bo |
|
| April 28, 2025 |
(Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed April 28, 2025) EX-10.1 Exhibit 10.1 April 28, 2025 Ashley McEvoy VIA ELECTRONIC DELIVERY Subject: Offer of Employment Dear Ashley: Insulet Corporation (the “Company”) is pleased to offer you the full-time position of President and Chief Executive Officer (“CEO”) reporting to the Company’s Board of Directors (the “Board”), effective April 28, 2025 (your “Start Date”). We are very excited about your taking on this |
|
| April 28, 2025 |
eparation Agreement between James R. Hollingshead and Insulet Corporation, EX-10.2 Exhibit 10.2 EXECUTION VERSION April 28, 2025 VIA EMAIL DELIVERY James R. Hollingshead Re: Severance Agreement and Release Dear Jim: The purpose of this letter (“Agreement”) is to memorialize our agreed amicable arrangement to end your employment relationship, to release the Insulet Corporation (the “Company”), from all legally waivable claims and to permit you to receive (i) severance pay |
|
| April 28, 2025 |
EX-99.1 Exhibit 99.1 Insulet Appoints Ashley McEvoy President and CEO Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance ACTON, Mass. – Apr. 28, 2025 – Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley |
|
| April 28, 2025 |
Amended and Restated Executive Severance Plan, dated April 28, 2025. EX-10.3 Exhibit 10.3 INSULET CORPORATION AMENDED AND RESTATED EXECUTIVE SEVERANCE PLAN 1. Purpose. Insulet Corporation (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly held corporations, the |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) |
|
| April 9, 2025 |
Consulting Services Agreement by and between the Company and Mark Field, effective March 14, 2025 Exhibit 10.1 CONSULTING SERVICES AGREEMENT This CONSULTING SERVICES AGREEMENT (this “Agreement”) is made as of March 14, 2025, by and between Insulet Corporation, with offices located at 100 Nagog Park, Acton, MA 01720 (“Insulet”), and Mark Field, with an address on file with Insulet (“You”). WHEREAS, you are employed by Insulet and will be separating from Insulet on March 14, 2025 (the “Leave Dat |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2025 (March 20, 2025) INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 21, 2025 |
Exhibit 10.1 EXECUTION VERSION SEVENTH AMENDMENT TO CREDIT AGREEMENT SEVENTH AMENDMENT (this “Agreement”), dated as of March 20, 2025, among INSULET CORPORATION, a Delaware corporation (the “Borrower”), each Guarantor party hereto, the Lenders party hereto, each L/C Issuer and Swingline Lender party hereto and Morgan Stanley Senior Funding, Inc., as administrative agent for the Lenders (in such ca |
|
| March 21, 2025 |
Exhibit 4.1 INSULET CORPORATION as Issuer, the Guarantors party hereto from time to time, AND COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee 6.50% Senior Notes due 2033 INDENTURE Dated as of March 20, 2025 Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01 Definitions 1 SECTION 1.02 Other Definitions 59 SECTION 1.03 [Reserved] 62 SECTION 1.04 Ru |
|
| March 21, 2025 |
Exhibit 10.2 CALL OPTION TERMINATION AGREEMENT dated as of [ ], 2025 Between INSULET CORPORATION and [ ] THIS CALL OPTION TERMINATION AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of [ ], 2025, between Insulet Corporation (“Company”) and [ ] (“Dealer”). WHEREAS, Company issued $800,000,000 principal amount of 0.375% Convertible |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 18, 2025 |
Insulet Announces Proposed Financing Transactions EX-99.1 Exhibit 99.1 Insulet Announces Proposed Financing Transactions ACTON, Mass., March 18, 2025 — Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured no |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 18, 2025 |
Insulet Announces Pricing of Senior Notes Due 2033 Exhibit 99.1 Insulet Announces Pricing of Senior Notes Due 2033 ACTON, Mass., March 18, 2025 — Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”). The Notes will bear inter |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 10, 2025 |
Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. OMISSIONS ARE MARKED [***] ADDENDUM TO THE PURCHASE AGREEMENT THIS ADDENDUM TO THE PURCHASE AGREEMENT (“2025 Addendum”) is entered into by and between Insulet Corporation (“Insulet”) and NXP USA, Inc. (“NXP”) and effective as |
|
| February 21, 2025 |
Form of Insulet Corporation 2017 Stock Option and Incentive Plan Exhibit 10.2 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT COVER SHEET Insulet Corporation, a Delaware corporation (the “Company”), hereby grants restricted stock units (“RSUs”) for shares of the Company’s common stock, par value $0.001 (the “Stock”), to you, subject to the vesting and other conditions set forth in this Insulet Corporation 2017 Stock Opti |
|
| February 21, 2025 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Insulet Asia (Singapore) Pte. Ltd. Singapore Insulet Austria GmbH Austria Insulet Australia Pty Ltd Australia Insulet Canada Corporation Canada Insulet Consulting (Shenzhen) Co., Ltd. China Insulet France SAS France Insulet Germany GmbH Germany Insulet Guadalajara, S. de R.L. de C.V. Mexico Insulet Internation |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33462 INSULET |
|
| February 21, 2025 |
orm of Insulet Corporation 2017 Stock Option and Incentive Plan Non-Qualified Stock Op Exhibit 10.1 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT Cover Sheet Insulet Corporation, a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Stock”), to you, subject to the vesting and other conditions set forth in this Insulet Corporation |
|
| February 21, 2025 |
rporation Amended and Restated Ins EXHIBIT 19.1 INSULET CORPORATION AMENDED AND RESTATED INSIDER TRADING POLICY Insulet Corporation (the “Company”) has adopted this Policy to promote compliance with, and prevent violations of, insider trading laws by Company employees, officers, members of the Board of Directors (“Directors”) and consultants and to avoid even the appearance of improper conduct by these persons. The Policy is design |
|
| February 21, 2025 |
Form of Insulet Corporation 2017 Stock Option and Incentive Plan Exhibit 10.3 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT Name of Grantee: «FirstName» «LastName» Number of Restricted Stock Units Granted: «UnitsGranted»(the “Target Award”) Grant Date: «GrantDate» Pursuant to the Insulet Corporation 2017 Stock Option and Incentive Plan (the “Plan”), Insulet Corporation (the “Company”) hereby grants an award under Sect |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 20, 2025 |
Exhibit 99.1 Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion ACTON, Mass. - February 20, 2025 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology w |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2025 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 4, 2024 |
EXHIBIT 99.1 Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court Jury awards $452 million in damages ACTON, Mass. - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co |
|
| November 12, 2024 |
PODD / Insulet Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name o |
|
| November 7, 2024 |
Exhibit 99.1 Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1) Raising Full Year Revenue and Margin Guidance ACTON, Mass. - November 7, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months e |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Reg |
|
| August 9, 2024 |
EXHIBIT 10.4 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. OMISSIONS ARE MARKED *** AMENDMENT NO. 4 to the AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This Amendment No. 4 to the Amended and Restated Development and Commercialization Agreement (“Amendment”) is dat |
|
| August 9, 2024 |
EXHIBIT 10.3 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. OMISSIONS ARE MARKED *** CONFIDENTIAL AMENDMENT NO. 3 TO AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This Amendment No. 3 to the Amended and Restated Development and Commercialization Agreement ("Amendment |
|
| August 8, 2024 |
Exhibit 99.1 Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue, Gross Margin and Operating Margin Guidance ACTON, Mass. - August 8, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months end |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 5, 2024 |
Exhibit 10.1 Execution Version SIXTH AMENDMENT TO CREDIT AGREEMENT SIXTH AMENDMENT (this “Agreement”), dated as of August 2, 2024, among INSULET CORPORATION, a Delaware corporation (the “Borrower”), each Guarantor party hereto, the Lenders party hereto and Morgan Stanley Senior Funding, Inc., as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), to the Credit Agre |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2024 (August 2, 2024) INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33462 04-3523891 (State or other jurisdiction of incorporation) |
|
| July 26, 2024 |
EXHIBIT 99.1 Insulet Reports Preliminary Second Quarter 2024 Revenue Results Second Quarter Revenue Increased 23% Year-Over-Year Raising Full Year 2024 Total Omnipod Revenue Outlook ACTON, Mass. - July 26, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced certain preliminary |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 30, 2024 |
Insulet Corporation Conflict Minerals Report For Calendar Year 2023 Exhibit 1.01 Insulet Corporation Conflict Minerals Report For Calendar Year 2023 Insulet Corporation (“Insulet,” the “Company,” “we,” “us,” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2023 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (the “SEC”) |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-33462 04-3523891 (Commission File Number) (IRS Employer Identification No.) 100 Nagog Park Acton, Massachusetts 01720 (Address of principal |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 20, 2024 |
EXHIBIT 10.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. OMISSIONS ARE MARKED [***] ADDENDUM TO THE PURCHASE AGREEMENT THIS ADDENDUM TO THE PURCHASE AGREEMENT (“Addendum”) is entered into by and between Insulet Corporation (“Insulet”) and NXP USA, Inc. (“NXP”) and effective as of Ja |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 10, 2024 |
Chadwick and Insulet Corporation dated Marc EXHIBIT 10.1 Insulet Corporation 100 Nagog Park, Acton, MA 01720 March 4, 2024 Ana Maria Chadwick [Address] Dear Ana, Insulet Corporation is pleased to offer you the full-time position of EVP, Chief Financial Officer, reporting directly to Jim Hollingshead, President and CEO. We are excited about the prospect of you joining Insulet and look forward to your meaningful contribution to the team. This |
|
| May 10, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Re |
|
| May 9, 2024 |
Exhibit 99.1 Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue and Operating Margin Guidance ACTON, Mass. - May 9, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2024. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 9, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Prox |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONF |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 20, 2024 |
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer Exhibit 99.1 Insulet Appoints Ana Maria Chadwick as Chief Financial Officer ACTON, Mass.— March 20, 2024— Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22 |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 1, 2024 |
Exhibit 10.3 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT Name of Grantee: «FirstName» «LastName» Number of Restricted Stock Units Granted: «UnitsGranted» (the “Target Award”) Grant Date: «GrantDate» Pursuant to the Insulet Corporation 2017 Stock Option and Incentive Plan (the “Plan”), Insulet Corporation (the “Company”) hereby grants an award under Sec |
|
| March 1, 2024 |
Exhibit 10.2 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT COVER SHEET Insulet Corporation, a Delaware corporation (the “Company”), hereby grants restricted stock units (“RSUs”) for shares of the Company’s common stock, par value $0.001 (the “Stock”), to you, subject to the vesting and other conditions set forth in this Insulet Corporation 2017 Stock Opti |
|
| March 1, 2024 |
Exhibit 10.1 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT Cover Sheet Insulet Corporation, a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Stock”), to you, subject to the vesting and other conditions set forth in this Insulet Corporation |
|
| February 23, 2024 |
EXHIBIT 10.58 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED *** AMENDMENT NO. 2 TO AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This Amendment No. 2 (“Amendment”) is dated June 6, 2022 BETWEEN (1) Abbott Diabetes Care Inc., a Delaware corporation having i |
|
| February 23, 2024 |
EXHIBIT 10.56 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED *** CONFIDENTIAL AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of September 13, 2021 (the |
|
| February 23, 2024 |
Insulet Corporation Compensation Recoupment Policy EXHIBIT 97.1 INSULET CORPORATION COMPENSATION RECOUPMENT POLICY Recoupment of Incentive-Based Compensation It is the policy of Insulet Corporation (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements (including any such correction that is material to the previously issued financial statements, or that would result in |
|
| February 23, 2024 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Insulet Asia (Singapore) Pte. Ltd. Singapore Insulet Austria GmbH Austria Insulet Australia Pty Ltd Australia Insulet Canada Corporation Canada Insulet Consulting (Shenzhen) Co., Ltd. China Insulet France SAS France Insulet Germany GmbH Germany Insulet International Holdings Ltd. United Kingdom Insulet Interna |
|
| February 23, 2024 |
EXHIBIT 10.64 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS TREATED AS CONFIDENTIAL BY THE COMPANY. OMISSIONS ARE MARKED [***] AMENDMENT NO. 1 TO PURCHASE AGREEMENT This Amendment No. 1 to Purchase Agreement (this "Amendment No. 1") is dated as of the 30th day of November, 2019 (the "Amendment Effective Date"), by and between lnsulet Corporation |
|
| February 23, 2024 |
EXHIBIT 10.59 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”), entered into as of October 12, 2017 (“Effective Date”) by and between Insulet Corporation, a Delaware corporation, having a place of business at 6 |
|
| February 23, 2024 |
Lauren Budden and Insulet Corporation, dated EXHIBIT 10.33 Insulet Corporation 100 Nagog Park, Acton, MA 01720 January 22, 2024 Private & Confidential Lauren Budden [address on file] Dear Lauren This letter sets out the temporary change in compensation that will apply for the period of time that you cover the role of Interim Chief Financial Officer, the “Secondment”. The allowance will commence on October 23, 2023 and is anticipated to end b |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33462 INSULET |
|
| February 23, 2024 |
EXHIBIT 10.57 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED *** AMENDMENT NO. 1 to the AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This Amendment No. 1 to the Amended and Restated Development and Commercialization Agreement (“Amendment”) is dated as of t |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 22, 2024 |
Exhibit 99.1 Insulet Reports Full Year 2023 Revenue Increase of 30% (30% constant currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% constant currency) Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass. - February 22, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump t |
|
| February 13, 2024 |
PODD / Insulet Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01197-insuletcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Insulet Corp Title of Class of Securities: Common Stock CUSIP Number: 45784P101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 9, 2024 |
PODD / Insulet Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 9, 2024 |
PODD / Insulet Corporation / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 8, 2024 |
PODD / Insulet Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Insulet Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 25, 2024 |
Exhibit 10.1 Execution Version FIFTH AMENDMENT TO CREDIT AGREEMENT FIFTH AMENDMENT (this “Agreement”), dated as of January 24, 2024, among INSULET CORPORATION, a Delaware corporation (the “Borrower”), each Guarantor party hereto, the Lenders party hereto and Morgan Stanley Senior Funding, Inc., as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), to the Credit Ag |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2024 INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33462 04-3523891 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2024 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 18, 2024 |
Exhibit 99.1 Insulet Announces Changes to Board of Directors with Retirements and New Appointments Flavia Pease and Timothy Stonesifer to join Board of Directors Shacey Petrovic and Corinne Nevinny to retire from the Board at the Company’s 2024 Annual Meeting ACTON, Mass.— January 18, 2024 — (BUSINESS WIRE)— Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless |
|
| November 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name o |
|
| November 2, 2023 |
As filed with the Securities and Exchange Commission on November 2, 2023 As filed with the Securities and Exchange Commission on November 2, 2023 Registration No. |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 2, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) INSULET CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 Par |
|
| November 2, 2023 |
Exhibit 99.1 Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency1) Raised Full Year Revenue Guidance to a Range of 26% to 27%, including Total Omnipod of 29% to 30% ACTON, Mass. - November 2, 2023 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, toda |
|
| November 2, 2023 |
Exhibit 10.1 INSULET CORPORATION DEFERRED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS This Insulet Corporation Deferred Compensation Plan for Non-Employee Directors (this “Plan”) has been adopted by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Insulet Corporation (the “Company”) to govern the deferral of cash fees and restricted stock units (“RSUs”) by m |
|
| October 3, 2023 |
Insulet Announces CFO Transition Reaffirms Guidance for Third Quarter and Fiscal Year 2023 Exhibit 99.1 Insulet Announces CFO Transition Reaffirms Guidance for Third Quarter and Fiscal Year 2023 ACTON, Mass. – October 3, 2023 – Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Wayde McMillan has decided to step down from his role as Executive Vice President, Chief F |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Reg |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 8, 2023 |
UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS Exhibit 99.1 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS INSULET CORPORATION, : : Plaintiff, : : Case No. 1:23-cv-11780 v. : : JURY TRIAL DEMANDED EOFLOW CO., LTD.; EOFLOW, INC.; : FLEX, LTD.; FLEXTRONICS : CORPORATION; FLEXTRONICS : MEDICAL SALES AND MARKETING, : LTD.; LUIS J. MALAVE; STEVEN : DIIANNI; and IAN G. WELSFORD, : : Defendants. : : COMPLAINT FOR MISAPPROPRIATION AND INFRINGE |
|
| August 8, 2023 |
Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency1) Exhibit 99.1 Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency1) ACTON, Mass. - August 8, 2023 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Hi |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2023 INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33462 04-3523891 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 12, 2023 |
EX-10.1 Exhibit 10.1 Execution Version FOURTH AMENDMENT TO CREDIT AGREEMENT FOURTH AMENDMENT (this “Agreement”), dated as of June 9, 2023, among INSULET CORPORATION, a Delaware corporation (the “Borrower”), each Guarantor party hereto, the Lenders party hereto, each L/C Issuer and Swingline Lender party hereto and Morgan Stanley Senior Funding, Inc., as administrative agent for the Lenders (in suc |
|
| June 7, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 7, 2023 |
Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] AMENDMENT NUMBER 21 TO THE SUPPLY AGREEMENT BY AND BETWEEN AMGEN INC. AND INSULET CORPORATION This Amendment Number 21 (“Amendment”) is entered into effective as of June 1st, 2023 (“Amendment Effective Date”) b |
|
| May 30, 2023 |
Insulet Corporation Conflict Minerals Report For Calendar Year 2022 Exhibit 1.01 Insulet Corporation Conflict Minerals Report For Calendar Year 2022 Insulet Corporation (“Insulet,” the “Company,” “we,” “us,” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2022 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (the “SEC”) |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-33462 04-3523891 (Commission File Number) (IRS Employer Identification No.) 100 Nagog Park Acton, Massachusetts 01720 (Address of principal |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 5, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Re |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 4, 2023 |
Exhibit 10.1 CONSULTING SERVICES AGREEMENT This CONSULTING SERVICES AGREEMENT (this “Agreement”) is made as of May 2, 2023, by and between Insulet Corporation, with offices located at 100 Nagog Park, Acton, MA 01720 (“Insulet”), and Bret Christensen, with an address on file with Insulet (“You”). WHEREAS, you are employed by Insulet and will be separating from Insulet on May 5, 2023 (the “Leave Dat |
|
| May 4, 2023 |
Exhibit 99.1 Insulet Announces New Organizational Structure to Drive Further Growth Structured to Accelerate Innovation and Commercialization Priorities Creates New Roles to Oversee Product & End-to-End Customer Experience and Technology ACTON, Mass. – May 4, 2023 – Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® |
|
| May 4, 2023 |
Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1) Exhibit 99.1 Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1) ACTON, Mass. - May 4, 2023 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2023. First Quarter Financial Highli |
|
| April 10, 2023 |
PODD / Insulet Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Insulet Corp. Title of Class of Securities: Common Stock CUSIP Number: 45784P101 Date of Event Which Requires Filing of this Statement: March 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CON |
|
| April 6, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Prox |
|
| February 24, 2023 |
Exhibit 10.66 Insulet Corporation, Confidentiality, Non-Solicit, Non-Compete, and IP Assignment Agreement This Confidentiality, Non-Solicit, Non-Compete, and IP Assignment Agreement (“Agreement”) is entered into between the undersigned individual (“I”, “me”, or “Employee”) and Insulet Corporation (collectively, the “Company”). I understand the Company is engaged in the business of designing, devel |
|
| February 24, 2023 |
Amendment Number 20 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation Exhibit 10.59 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] AMENDMENT NUMBER 20 TO THE SUPPLY AGREEMENT BY AND BETWEEN AMGEN INC. AND INSULET CORPORATION This Amendment Number 20 (“Amendment”), entered into effective as of June 25, 2021 (“Amendment 20 Effective Date”), |
|
| February 24, 2023 |
Amendment Number 19 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation Exhibit 10.58 DocuSign Envelope ID: FC8041F1-BC4A-4CAD-A973-3E361FB5E7A4 Contract Number CW2146852 Amendment Number 19 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] AMENDMENT NUMBER 19 TO THE SUPPLY AGREEMENT BY AND BETWEEN AMGEN INC. AND INSULET CORPORATION This Amend |
|
| February 24, 2023 |
Amendment Number 15 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation Exhibit 10.55 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] AMENDMENT NUMBER 15 TO THE SUPPLY AGREEMENT BY AND BETWEEN AMGEN INC. AND INSULET CORPORATION This Amendment Number 15 ("Amendment"), entered into effective as of July 12, 2017 ("Amendment 15 Effective Date"), |
|
| February 24, 2023 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Insulet Asia (Singapore) Pte. Ltd. Singapore Insulet Austria GmbH Austria Insulet Australia Pty Ltd Australia Insulet Canada Corporation Canada Insulet Consulting (Shenzhen) Co., Ltd. China Insulet France SAS France Insulet Germany GmbH Germany Insulet International Holdings Ltd. United Kingdom Insulet Interna |
|
| February 24, 2023 |
Exhibit 99.1 Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (24% constant currency) Represents 7th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass. - February 23, 2023 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump t |
|
| February 24, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33462 INSULET COR |
|
| February 24, 2023 |
Exhibit 10.53 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] MASTER EQUIPMENT AND SERVICES AGREEMENT AMENDMENT #2 THIS AMENDMENT AND RESTATEMENT AGREEMENT #2 to the MASTER EQUIPMENT AND SERVICES AGREEMENT originally dated August 31, 2016 between Insulet Corporation and |
|
| February 24, 2023 |
Amendment Number 18 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation Exhibit 10.57 Amgen Proprietary - Confidential Contract Number CW2146852 Amendment Number 18 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] AMENDMENT NUMBER 18 TO THE SUPPLY AGREEMENT BY AND BETWEEN AMGEN INC. AND INSULET CORPORATION This Amendment Number 18 ("Amendment |
|
| February 24, 2023 |
Amendment Number 17 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation Exhibit 10.56 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] AMENDMENT NUMBER 17 TO THE SUPPLY AGREEMENT BY AND BETWEEN AMGEN INC. AND INSULET CORPORATION This Amendment Number 17 ("Amendment''), entered into effective as of April 1, 2019 ("Amendment 17 Effective Date") |
|
| February 24, 2023 |
Exhibit 10.30 Insulet Corporation INVENTIONS, NON-DISCLOSURE, NON-SOLICITATION, NON-SERVICING AND NON-COMPETITION AGREEMENT [Date] In consideration of my employment by Insulet Corporation, its successors, affiliates, parents, subsidiaries and subdivisions (collectively, the "Company") and the wages, benefits, training opportunities, and other terms and conditions of that employment, I hereby coven |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2023 (February 23, 2023) INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdict |
|
| February 24, 2023 |
Exhibit 10.52 THIS AMENDMENT AND RESTATEMENT AGREEMENT to the MASTER EQUIPMENT AND SERVICES AGREEMENT originally dated August 31, 2016 between lnsulet Corporation and ATS Automation Tooling Systems Inc., (the "MESA") is made and entered into as of 31 August 2021 by and between: 1.lnsulet Corporation, with offices at 100 Nagog Park Acton, MA 01720 ("lnsulet"); and 2.ATS Automation Tooling Systems I |
|
| February 24, 2023 |
Exhibit 10.54 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] MANUFACTURING SERVICES AND LINE RETENTION AGREEMENT July 29, 2022 Insulet Corporation 100 Nagog Park Acton, Massachusetts 01720 (herein referred to as “INSULET”) RE: Manufacturing Services Agreement (“Agreemen |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 23, 2023 |
Exhibit 99.1 Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency) Represents 7th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass. - February 23, 2023 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump t |
|
| February 22, 2023 |
EX-10.3 4 podd-2023x02x22ex103.htm EX-10.3 Exhibit 10.3 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT Name of Grantee: Number of Restricted Stock Units Granted: Grant Date: Pursuant to the Insulet Corporation 2017 Stock Option and Incentive Plan (the “Plan”), Insulet Corporation (the “Company”) hereby grants an award under Section 10 of the Plan of the t |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 22, 2023 |
Exhibit 10.5 INSULET CORPORATION ANNUAL INCENTIVE PLAN SECTION 1. BACKGROUND, PURPOSE AND DURATION 1.1Effective Date. Insulet Corporation established this Insulet Corporation Annual Incentive Plan effective as of January 1, 2023 (“Effective Date”). 1.2Purpose of the Plan. The Plan is designed to motivate Company employees to achieve certain pre-established Company and individual objectives by prov |
|
| February 22, 2023 |
Exhibit 10.1 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT Cover Sheet Insulet Corporation, a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Stock”), to you, subject to the vesting and other conditions set forth in this Insulet Corporation |
|
| February 22, 2023 |
Exhibit 10.4 INSULET CORPORATION AMENDED AND RESTATED EXECUTIVE SEVERANCE PLAN 1.Purpose. Insulet Corporation (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly held corporations, the possibil |
|
| February 22, 2023 |
Exhibit 10.2 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT COVER SHEET Insulet Corporation, a Delaware corporation (the “Company”), hereby grants restricted stock units (“RSUs”) for shares of the Company’s common stock, par value $0.001 (the “Stock”), to you, subject to the vesting and other conditions set forth in this Insulet Corporation 2017 Stock Opti |
|
| February 22, 2023 |
Exhibit 10.6 CONSULTING SERVICES AGREEMENT This CONSULTING SERVICES AGREEMENT (this “Agreement”) is made as of February , 2023, by and between Insulet Corporation, with offices located at 100 Nagog Park, Acton, MA 01720 (“Insulet”), and Charles J. Alpuche, with an address on file with Insulet (“You”). WHEREAS, you are employed by Insulet and have announced your intention to retire on March 31, 202 |
|
| February 14, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2023 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 14, 2023 |
Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***] PATENT ASSIGNMENT AND LICENSE AGREEMENT This Patent Assignment and License Agreement (this “Agreement”, as further defined below) is made and entered into as of this 9th day of February, 2023 (the “Effective Da |
|
| February 13, 2023 |
PODD / Insulet Corporation / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 13, 2023 |
PODD / Insulet Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 9, 2023 |
PODD / Insulet Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01157-insuletcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Insulet Corp. Title of Class of Securities: Common Stock CUSIP Number: 45784P101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rul |
|
| February 6, 2023 |
PODD / Insulet Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Insulet Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 1, 2022 |
Exhibit 10.2 THIRD AMENDMENT TO CREDIT AGREEMENT THIRD AMENDMENT (this ?Agreement?), dated as of November 30, 2022, among INSULET CORPORATION, a Delaware corporation (the ?Borrower?), the Guarantor party hereto, the Lenders party hereto, each L/C Issuer and Swingline Lender party hereto and Morgan Stanley Senior Funding, Inc., as administrative agent for the Lenders (in such capacity, the ?Adminis |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2022 INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33462 04-3523891 (State or other jurisdiction of incorporation) (Commission F |
|
| December 1, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT SECOND AMENDMENT (this ?Agreement?), dated as of November 30, 2022, among INSULET CORPORATION, a Delaware corporation (the ?Borrower?) and Morgan Stanley Senior Funding, Inc., as administrative agent for the Lenders (in such capacity, the ?Administrative Agent?), to the Credit Agreement, dated as of May 4, 2021 (as amended, amended and restated, ex |
|
| November 14, 2022 |
Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 Controller Exhibit 99.1 Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod? 5 Controller ACTON, Mass.? November 14, 2022 ? Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), today announced a Medical Device Correction for the Omnipod? 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 Controller charging port and cable. This does not impact the O |
|
| November 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name o |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 3, 2022 |
Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1) Exhibit 99.1 Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1) ACTON, Mass. - November 3, 2022 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, today announced financial results for the three months ended September 30, 2022. Third Quarter Financi |
|
| October 17, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 17, 2022 |
Exhibit 99.1 October 17, 2022 URGENT: Medical Device Correction REF: 9056196-10/11/2022-001-C Urgent Information Regarding the Omnipod DASH® Insulin Management System Affected Product: Device Description Part Numbe UDI Serial Numbe Omnipod DASH® Personal Diabetes Manager 18239 18341-USA-ENG 10385082000009 20385082000006 All serial number Please read this notice in its entirety and acknowledge rece |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 5, 2022 |
Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. AMENDMENT NO. 1 TO DEVELOPMENT AGREEMENT This Amendment No. 1 to Development Agreement (this "Amendment No. 1") is made and entered into November 21, 2019 (the "Effective Date"), by and between |
|
| August 5, 2022 |
Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. COMMERCIALIZATION AGREEMENT This Commercialization Agreement (this ?Agreement?) is made and entered into as of November 21, 2019 (the ?Effective Date?) by and between Insulet Corporation, a Dela |
|
| August 5, 2022 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. DEVELOPMENT AGREEMENT This Development Agreement (this ?Agreement?) is made and entered into on December 7, 2016 (the ?Effective Date?) by and between Insulet Corporation, a Delaware corporation |
|
| August 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Reg |
|
| August 5, 2022 |
Exhibit 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. DATA AGREEMENT This Data Agreement (the ?Agreement?) is made and entered into as of May 7, 2020 (the ?Effective Date?) by and between Insulet Corporation, a Delaware corporation having a princip |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 4, 2022 |
Exhibit 99.1 Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1) Recently Launched U.S. Full Market Release for Omnipod? 5 - Now Available through Retail Pharmacies ACTON, Mass. - August 4, 2022 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, tod |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33462 04-3523891 (State or other jurisdiction of incorporation) (Commission File |
|
| June 16, 2022 |
Exhibit 10.1 EXECUTION VERSION INCREMENTAL AMENDMENT TO CREDIT AGREEMENT INCREMENTAL AMENDMENT (this ?Agreement?), dated as of June 15, 2022, among INSULET CORPORATION, a Delaware corporation (the ?Borrower?), the Guarantor party hereto, the Lenders party hereto, each L/C Issuer and Swingline Lender party hereto and Morgan Stanley Senior Funding, Inc., as administrative agent for the Lenders (in s |
|
| May 31, 2022 |
Insulet Corporation Conflict Minerals Report For Calendar Year 2021 EX-1.01 2 exhibit101cmrsd2022-05x31.htm EX-1.01 Exhibit 1.01 Insulet Corporation Conflict Minerals Report For Calendar Year 2021 Insulet Corporation (“Insulet,” the “Company,” “we” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2021 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Secur |
|
| May 31, 2022 |
SD 1 formsd2022-05x31.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-33462 04-3523891 (Commission File Number) (IRS Employer Identification No.) 100 Nagog Park Acton, Massachusett |
|
| May 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 6, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Re |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2022 (May 4, 2022) INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 6, 2022 |
Exhibit 10.1 May 4, 2022 Mr. James R. Hollingshead VIA ELECTRONIC DELIVERY Dear Jim: Insulet Corporation (?Company?) is pleased to offer you the full-time position of President and Chief Executive Officer (?CEO?) reporting to the Company?s Board of Directors (the ?Board?), effective June 1, 2022 (your ?start date?). We are very excited about your taking on this new role and look forward to your co |
|
| May 6, 2022 |
Exhibit 99.1 Insulet Announces CEO Transition Director Jim Hollingshead to Succeed Shacey Petrovic as President and CEO, Effective June 1, 2022 Petrovic and Hollingshead to Continue as Members of Insulet?s Board of Directors ACTON, Mass. ? May 5, 2022 ? Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of prod |
|
| May 6, 2022 |
Exhibit 10.2 RETIREMENT AND ADVISORY AGREEMENT This Retirement and Advisory Agreement (the ?Agreement?), is made as of May 4, 2022 by and between Insulet Corporation, a Delaware corporation (together with its successors and assigns, the ?Company?), and Shacey Petrovic (the ?Executive?). W I T N E S E T H: WHEREAS, the Company has employed the Executive as its President and Chief Executive Officer, |
|
| May 5, 2022 |
Insulet Reports First Quarter 2022 Revenue Increase of 17% Exhibit 99.1 Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year ACTON, Mass. - May 5, 2022 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, today announced financial results for the three months ended March 31, 2022. First Quarter Financial Highlights: ?First quarter 2022 |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 18, 2022 |
April 18, 2022 Wayde McMillan Executive Vice President & Chief Financial Officer Insulet Corporation 100 Nagog Park Acton, Massachusetts 01720 Via Edgar U. |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.? ) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFID |
|
| April 12, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.? ) ? Filed by the Registrant ? ? ?? Filed by a Party other than the Registrant Check the appropriate box: ?? ? ? Prelimin |
|
| March 1, 2022 |
Exhibit 10.1 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN PERFORMANCE SHARES AGREEMENT Name of Grantee: ?FirstName? ?LastName? Number of Restricted Stock Units Granted: (the ?Target Award?) Grant Date: ?GrantDate? Pursuant to the Insulet Corporation 2017 Stock Option and Incentive Plan (the ?Plan?), Insulet Corporation (the ?Company?) hereby grants an award under Section 10 of the Plan |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2022 INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 24, 2022 |
Exhibit 10.1 INSULET CORPORATION 2017 STOCK OPTION AND INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT Cover Sheet Insulet Corporation, a Delaware corporation (the ?Company?), hereby grants an option (the ?Option?) to purchase shares of the Company?s common stock, par value $0.001 per share (the ?Stock?), to you, subject to the vesting and other conditions set forth in this Insulet Corporation |
|
| February 24, 2022 |
Exhibit 10.43 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. MATERIALS SUPPLIER AGREEMENT BETWEEN INSULET CORPORATION AND SANMINA CORPORATION INSULET CORPORATION ? SANMINA CORPORATION MATERIALS SUPPLIER AGREEMENT TABLE OF CONTENTS 1. General 2. Term of Agreement 3. Pro |
|
| February 24, 2022 |
Exhibit 10.44 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [***]. CONFIDENTIAL FIRST AMENDMENT TO MATERIALS SUPPLIER AGREEMENT This First Amendment to the Materials Supplier Agreement (this ?Amendment?) is made effective as of October 1, 2020 (the ?Amendment Effective Date? |
|
| February 24, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33462 INSULET COR |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 24, 2022 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Insulet Asia (Singapore) Pte. Ltd. Singapore Insulet Austria GmbH Austria Insulet Australia Pty Ltd Australia Insulet Canada Corporation Canada Insulet Consulting (Shenzhen) Co., Ltd. China Insulet France SAS France Insulet Germany GmbH Germany Insulet International Holdings Ltd. United Kingdom Insulet Interna |
|
| February 24, 2022 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF INSULET CORPORATION (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place ma |
|
| February 23, 2022 |
Exhibit 99.1 Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year Represents 6th Consecutive Year of Over 20% Revenue Growth; Annual Revenue Surpasses $1 Billion Omnipod 5 Automated Insulin Delivery System Receives U.S. FDA Clearance ACTON, Mass. - February 23, 2022 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the g |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 11, 2022 |
PODD / Insulet Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2022 |
PODD / Insulet Corporation / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2022 |
PODD / Insulet Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Insulet Corp. Title of Class of Securities: Common Stock CUSIP Number: 45784P101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 4, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 7, 2022 |
Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine Exhibit 99.1 Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine ACTON, Mass. - Feb. 7, 2022 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, today announced that Elizabeth ?Bess? Weatherman has been appointed to the Company?s Board of Directors. Ms. Weat |
|
| January 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2022 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 31, 2022 |
Exhibit 99.1 Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control ACTON, MA - January 28, 2022 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received clearance from the U.S. Food and Drug Adm |
|
| November 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name o |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 4, 2021 |
Insulet Reports Third Quarter 2021 Revenue Increase of 18% Exhibit 99.1 Insulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year ACTON, MA - November 4, 2021 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, today announced financial results for the three months ended September 30, 2021. Third Quarter Financial Highlights: ?Third quarte |
|
| October 18, 2021 |
Exhibit 99.1 Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford ACTON, MA - October 18, 2021 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, today announced that Luciana Borio, M.D., has been appointed to the Company?s Board |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Reg |
|
| August 5, 2021 |
Insulet Reports Second Quarter 2021 Revenue Increase of 16% Exhibit 99.1 Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year ACTON, MA - August 5, 2021 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, today announced financial results for the three months ended June 30, 2021. Second Quarter Financial Highlights: ?Second quarter 20 |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 15, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 1, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 26, 2021 |
Insulet Corporation Conflict Minerals Report For Calendar Year 2020 EX-1.01 2 exhibit101cmrsd.htm EX-1.01 Exhibit 1.01 Insulet Corporation Conflict Minerals Report For Calendar Year 2020 Insulet Corporation (“Insulet,” the “Company,” “we” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2020 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report INSULET CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-33462 04-3523891 (Commission File Number) (IRS Employer Identification No.) 100 Nagog Park Acton, Massachusetts 01720 (Address of principal |
|
| May 14, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 7, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name of Re |
|
| May 6, 2021 |
Insulet Reports First Quarter 2021 Revenue Increase of 27% Exhibit 99.1 Insulet Reports First Quarter 2021 Revenue Increase of 27% Year-Over-Year ACTON, MA - May 6, 2021 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod? brand of products, today announced financial results for the three months ended March 31, 2021. First Quarter Financial Highlights: ?First quarter 2021 re |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 5, 2021 |
Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT Dated as of May 4, 2021 among INSULET CORPORATION, as the Initial Borrower, MORGAN STANLEY SENIOR FUNDING, INC., as Administrative Agent and Collateral Agent, THE LENDERS PARTY HERETO, MORGAN STANLEY SENIOR FUNDING, INC. and CITIGROUP GLOBAL MARKETS INC. as Joint Lead Arrangers and Joint Bookrunners for the Term B Facility and the Revolving Credit Fa |
|
| April 29, 2021 |
Insulet Announces Pricing of New Senior Secured Credit Facilities EX-99.1 2 d170094dex991.htm EX-99.1 Exhibit 99.1 Insulet Announces Pricing of New Senior Secured Credit Facilities ACTON, Mass., April 29, 2021 — Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the pricing of a $500 million senior secured term loan B facility (the term facility) a |
|
| April 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 19, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 19, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 19, 2021 |
Insulet Announces Launch of Syndication of New Credit Facilities EX-99.1 Exhibit 99.1 Insulet Announces Launch of Syndication of New Credit Facilities ACTON, Mass., April 19, 2021 — Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that it has launched the syndication of new senior secured credit facilities, comprised of a senior secured revolvin |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.? ) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? |
|
| April 13, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Prox |
|
| February 24, 2021 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Insulet Austria GmbH Austria Insulet Australia Pty Ltd Australia Insulet Canada Corporation Canada Insulet Consulting (Shenzhen) Co., Ltd. China Insulet France SAS France Insulet Germany GmbH Germany Insulet International Holdings Ltd. United Kingdom Insulet International Ltd. United Kingdom Insulet MA Securit |
|
| February 24, 2021 |
EX-10.57 3 podd-ex105720201231x10k.htm EX-10.57 Exhibit 10.57 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE MARKED [*]. SECOND AMENDMENT TO MATERIALS SUPPLIER AGREEMENT This Second Amendment to the Materials Supplier Agreement (this “Second Amendment”) is dated as of the 1st day of |
|
| February 24, 2021 |
Exhibit 10.56 March 19, 2020 Dan Manea Mendha, NJ Dear Dan: lnsulet Corporation ("Company") is pleased to offer you the full-time position of Senior Vice President, Chief Human Resources Officer reporting to me. We are excited about the prospect of you joining lnsulet and look forward to your meaningful contributions to the Company as we embark on an exciting new chapter in the Company's history. |
|
| February 24, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33462 INSULET COR |
|
| February 23, 2021 |
EX-99.1 2 podd202012-31ex991.htm EX-99.1 Exhibit 99.1 Insulet Reports Full Year 2020 Revenue Increase of 23% and Fourth Quarter 2020 Revenue Increase of 18% Year-Over-Year Represents 5th Consecutive Year of Over 20% Revenue Growth; Record Quarterly Revenue ACTON, MA - February 23, 2021 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technol |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2021 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Insulet Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45784P101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Insulet Corp. Title of Class of Securities: Common Stock CUSIP Number: 45784P101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 28, 2020 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 INSULET CORPORATION (Exact name o |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2020 INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 4, 2020 |
EX-99.1 2 podd2020-09x30xexx991.htm EX-99.1 Exhibit 99.1 Insulet Reports Third Quarter 2020 Revenue Increase of 22% Year-Over-Year Includes Total Omnipod® Revenue Growth of 20% ACTON, Mass. - November 4, 2020 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announ |
|
| October 20, 2020 |
Insulet Appoints Wayne A. I. Frederick, M.D., to Board of Directors EX-99.1 2 podd2020-10x20exx991.htm EX-99.1 Exhibit 99.1 Insulet Appoints Wayne A. I. Frederick, M.D., to Board of Directors ACTON, Mass.— Oct. 20, 2020 – Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Wayne A. I. Frederick, M.D., has been appointed |
